SCHEMBL13041753

SCHEMBL13041753

Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)cc(C3CC3)nc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.54
FLT3 P36888 12/20 0.54
KIT P10721 12/20 0.54
CSF1R P07333 12/20 0.54
BLK P51451 12/20 0.54
FLT1 P17948 12/20 0.54
LYN P07948 11/20 0.54
FLT4 P35916 10/20 0.54
LCK P06239 10/20 0.54
ABL1 P00519 8/20 0.54
SRC P12931 7/20 0.54
FYN P06241 7/20 0.54
PDGFRB P09619 1/20 0.49
ROCK2 O75116 7/20 0.49
MAP4K4 O95819 7/20 0.49
FGFR1 P11362 7/20 0.49
NEK2 P51955 7/20 0.49
ROCK1 Q13464 7/20 0.49
TAOK1 Q7L7X3 7/20 0.49
AURKB Q96GD4 7/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041757 0.92 KIT (0.52) KDRFLT3KITCSF1RBLK
SCHEMBL13041755 0.91 CSF1R (0.53) KDRFLT3KITCSF1RBLK
SCHEMBL13041780 0.90 KDR (0.64) KDRFLT3KITCSF1RBLK
SCHEMBL13041765 0.90 KDR (0.61) KDRFLT3KITCSF1RBLK
SCHEMBL13041758 0.90 KDR (0.50) KDRFLT3KITCSF1RBLK
SCHEMBL13041762 0.89 KDR (0.56) KDRFLT3KITCSF1RBLK
SCHEMBL2821104 0.89 KDR (0.70) KDRFLT3KITCSF1RBLK
SCHEMBL13041791 0.89 CSF1R (0.59) KDRFLT3KITCSF1RBLK
SCHEMBL13041811 0.89 KDR (0.53) KDRFLT3KITCSF1RBLK
SCHEMBL13041819 0.88 KDR (0.51) KDRFLT3KITCSF1RBLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
WO-2007144202-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-21 WO disclosed
EP-1867647-A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, TEK KDR 1/4885FLT3 116/4885KIT 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.